Genetically adjusted prostate-specific antigen more predictive of aggressive prostate cancer than unadjusted PSA<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 7, 2023 (HealthDay News) — Accounting for genetic determinants of constitutive, noncancer-related prostate-specific antigen (PSA) variation improves prediction of prostate cancer, according to a study published online June 1 in Nature Medicine<\/em>.<\/p>\n Linda Kachuri, Ph.D., M.P.H., from the University of California in San Francisco, and colleagues conducted a multiancestry meta-analysis of 95,768 men and developed a PSA polygenic score (PGSPSA<\/sub>) to account for constitutive PSA variation.<\/p>\n The researchers identified 128 genome-wide significant associations, and the resulting score accounted for 9.61 percent of constitutive PSA variation. In men of European ancestry, using PGS-adjusted PSA would avert up to 31 percent of negative prostate biopsies but also result in 12 percent fewer biopsies among patients with prostate cancer, mainly tumors with a Gleason score <7. Compared with unadjusted PSA, genetically adjusted PSA was more predictive of aggressive prostate cancer (odds ratio, 3.44 versus 3.31; area under the curve, 0.755 versus 0.738). Including genetically adjusted PSA improved detection of aggressive disease compared with a prostate cancer PGS alone (area under the curve, 0.786 versus 0.712).<\/p>\n “We adjusted each person’s PSA values based on his unique genetic profile,” Kachuri said in a statement. “PSA values personalized in this way are more likely to reveal changes in PSA due to prostate cancer because they are corrected for the influence of inherited genetics.”<\/p>\n Two authors disclosed ties to the biotechnology industry.<\/p>\n